Toward a core nutraceutical program for cancer management

Integrative Cancer Therapies

Volumn 5, Issue 2, 2006, Pages 150-171

  McCarty, Mark F ^a   Block, Keith I ^a  

^a Block Center for Integrative Cancer Care   (United States)

Author keywords

glucan; Fish oil; Hydroxymethylbutyrate; Modified citrus pectin; Salicylate

Indexed keywords

3 HYDROXYBUTYRIC ACID; BETA CAROTENE; BETA GLUCAN; CHROMIUM; COLECALCIFEROL DERIVATIVE; COPPER; EPIGALLOCATECHIN GALLATE; FISH OIL; GALECTIN 3; GALECTIN 3 ANTAGONIST; GLUTAMINE; GLYCINE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYCOPENE; MAGNESIUM; MODIFIED CITRUS PECTIN; NATTOKINASE; NUTRACEUTICAL; PECTIN; POLICOSANOL; PROBIOTIC AGENT; SALICYLIC ACID DERIVATIVE; SELENIUM; SILYMARIN; TAURINE; TETRATHIOMOLYBDIC ACID; TRACE ELEMENT; UNCLASSIFIED DRUG; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; CACHEXIA; CANCER; DRUG CAPSULE; DRUG FORMULATION; DRUG MEGADOSE; EXERCISE; HEALTH PROGRAM; HUMAN; IMMUNITY; LACTOBACILLUS; LOW FAT DIET; MACROPHAGE; METASTASIS; METASTASIS INHIBITION; MUSCLE ATROPHY; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; NUTRACEUTICAL PROGRAM; NUTRITIONAL INSURANCE FORMULA; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OSTEOLYSIS; OSTEOPENIA; POWDER; PRIORITY JOURNAL; REVIEW; TABLET; THROMBOEMBOLISM; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VEGETARIAN DIET;

ANIMALS; CACHEXIA; CHEMISTRY, PHARMACEUTICAL; HEALTH SERVICES NEEDS AND DEMAND; HEALTH STATUS; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MICRONUTRIENTS; NEOPLASM METASTASIS; NEOPLASMS; NUTRITION PHYSIOLOGY; OSTEOLYSIS, ESSENTIAL; PATIENT SATISFACTION; THROMBOEMBOLISM;

EID: 33646581315     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735406288443     Document Type: Review

References (343)

1. McCarty MF. A wholly nutritional "multifocal angiostatic therapy" for control of disseminated cancer. Med Hypotheses. 2003;61:1-15.
2. McCarty MF, Block KI. Multifocal angiostatic therapy - an update. Integr Cancer Ther. 2005;4:301-314.
3. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005;7:522-527.
4. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19:543-549.
5. Meromsky L, Lotan R, Raz A. Implications of endogenous tumor cell surface lectins as mediators of cellular interactions and lung colonization. Cancer Res. 1986;46:5270-5275.
6. Beuth J, Ko HL, Schirrmacher V, Uhlenbruck G, Pulverer G. Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan. Clin Exp Metastasis. 1988;6:115-120.
7. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, Metcalf JB. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res. 1996;56:5319-5324.
8. Inufusa H, Nakamura M, Adachi T, et al. Role of galectin-3 in adenocarcinoma liver metastasis. Jnt J Oncol. 2001;19:913-919.
9. Raz A, Meromsky L, Lotan R. Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells. Cancer Res. 1986;46:3667-3672.
10. Irimura T, Matsushita Y, Sutton RC, et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res. 1991;51:387-393.
11. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899-909.
12. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94:1854-1862.
13. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apaptosis. 2005;10:267-275.
14. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999;59:4148-4154.
15. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87:348-353.
16. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev. 2000;5:546-552.
17. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6:301-304.
18. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-2040.
19. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203-208.
20. Dumic J, Lauc G, Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem. 2000;10:149-158.
21. Liu L, Sakai T, Sano N, Fukui K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J. 2004;380:31-41.
22. Tozawa K, Sakurada S, Kohri K, Okamoto T. Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res. 1995;55:4162-4167.
23. Dhawan S, Singh S, Aggarwal BB. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997;27:2172-2179.
24. Andrews EJ, Wang JH, Winter DC, Laug WE, Redmond HP. Tumor cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression. J Surg Res. 2001;97:14-19.
25. Tozawa K, Kawai N, Hayashi Y, Sasaki S, Kohri K, Okamoto T. Gold compounds inhibit adhesion of human cancer cells to vascular endothelial cells. Cancer Lett. 2003;196:93-100.
26. Lloyd FP, Jr, Slivova V, Valachovicova T, Sliva D. Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol. 2003;23:1277-1283.
27. Andela VB, Gordon AH, Zotalis G, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. 2003:S75-S85.
28. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets. 2004;4:327-336.
29. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959.
30. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. Nature. 1998;396:77-80.
31. Futakuchi M, Ogawa K, Sano M, Tamano S, Takeshita F, Shirai T. Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma. Jpn J Cancer Res. 2002;93:1175-1181.
32. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T. Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci. 2004;95:18-24.
33. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 2000;60:2555-2561.
34. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001;282:671-677.
35. Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 2002;35:1117-1124.
36. Gao XQ, Han JX, Huang HY, Yan S, Song CZ, Huang HN. Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004;25:1327-1333.
37. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002;62:4854-4859.
38. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003;1:701-706.
39. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene. 2002;21:1759-1767.
40. Singleton PT, Jr. Salsalate: its role in the management of rheumatic disease. Clin Ther. 1980;3:80-102.
41. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 2002;62:381-385.
42. Demeule M, Brossard M, Page M, Gingras D, Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochem Biophys Acta. 2000;1478:51-60.
43. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer. 2001;91:822-832.
44. Sazuka M, Murakami S, Isemura M, Satoh K, Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett. 1995;98:27-31.
45. Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res. 2005;11:1918-1927.
46. Roitt IM, Delves PJ. Roitt's Essential Immunology. 10th ed. Malden, Mass: Blackwell; 2001.
47. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-156.
48. Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol. 2004;1:12-21.
49. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today. 1993;14:491-499.
50. Bubenik J. Tumour MHC class I downregulation and immunotherapy. Oncol Rep. 2003;10:2005-2008.
51. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells. Biol Trace Elem Res. 1996;52:227-239.
52. Kiremidjian-Schumacher L, Roy M. Selenium and immune function. Z Ernahrungswiss. 1998;37(suppl 1):50-56.
53. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res. 1994;41:115-127.
54. Wood SM, Beckham C, Yosioka A, Darban H, Watson RR. Beta-carotene and selenium supplementation enhances immune response in aged humans. Integr Med. 2000;2:85-92.
55. Petrie HT, Klassen LW, Klassen PS, O'Dell JR, Kay HD. Selenium and the immune response: 2. Enhancement of murine cytotoxic T-lymphocyte and natural killer cell cytotoxicity in vivo. J Leukoc Biol. 1989;45:215-220.
56. Nesaretnam K, Radhakrishnan A, Selvaduray KR, et al. Effect of palm oil carotene on breast cancer tumorigenicity in nude mice. Lipids. 2002;37:557-560.
57. Carlos TF, Riondel J, Mathieu J, Guiraud P, Mestries JC, Favier A. Beta-carotene enhances natural killer cell activity in athymic mice. In Vivo. 1997;11:87-91.
58. Santos MS, Meydani SN, Leka L, et al. Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. Am J Clin Nutr. 1996;64:772-777.
59. Santos MS, Gaziano JM, Leka LS, Beharka AA, Hennekens CH, Meydani SN. Beta-carotene-induced enhancement of natural killer cell activity in elderly men: an investigation of the role of cytokines. Am J Clin Nutr. 1998;68:164-170.
60. Tapazoglou E, Prasad AS, Hill G, Brewer GJ, Kaplan J. Decreased natural killer cell activity in patients with zinc deficiency with sickle cell disease. J Lab Clin Med. 1985;105:19-22.
61. Ozturk G, Erbas D, Imir T, Bor NM. Decreased natural killer (NK) cell acthity in zinc-deficient rats. Gen Pharmacol. 1994;25:1499-1503.
62. Prasad AS. Zinc and immunity. Mol Cell Biochem. 1998;188:63-69.
63. Bogden JD, Oleske JM, Lavenhar MA, et al. Effects of one year of supplementation with zinc and other micronutrients on cellular immunity in the elderly. J Am Coll Nutr. 1990;9:214-225.
64. Stephenson RA Luft BJ, Pedrotti PW, Remington JS. Inhibition of mouse natural killer cell activity by zinc. J Natl Cancer Inst. 1985;74:1067-1070.
65. Ibs KH, Rink L. Zinc-altered immune function. J Nutr. 2003;133:1452S-1456S.
66. Oshiman K, Fujimiya Y, Ebina T, Suzuki I, Noji M. Orally administered beta-1,6-D-polyglucose extracted from Agaricus blazei results in tumor regression in tumor-bearing mice. Planta Med. 2002;68:610-614.
67. See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest. 2002;31:137-153.
68. Lee YL, Kim HJ, Lee MS, et al. Oral administration of Agaricus blazei (H1 strain) inhibited tumor growth in a sarcoma 180 inoculation model. Exp Anim. 2003;52:371-375.
69. Takimoto H, Wakita D, Kawaguchi K, Kumazawa Y. Potentiation of cytotoxic activity in naive and tumor-bearing mice by oral administration of hot-water extracts from Agaricus brazei fruiting bodies. Biol Pharm Bull. 2004;27:404-406.
70. Ahn WS, Kim DJ, Chae GT, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004;14:589-594.
71. Kasai H, He LM, Kawamura M, et al. IL-12 production induced by Agaricus blazei raction H (ABH) involves toll-like receptor (TLR). Evid Based Complement Alternat Med. 2004;1:259-267.
72. Kobayashi H, Yoshida R, Kanada Y, et al. Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol. 2005;131:527-538.
73. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32:201-215.
74. Kohguchi M, Kunikata T, Watanabe H, et al. Immuno-potentiating effects of the antler-shaped fruiting body of Ganoderma lucidum (Rokkaku-Reishi). Biosci Biotechnol Biochem. 2004;68:881-887.
75. Gao Y, Gao H, Chan E, et al. Antitumor activity and underlying mechanisms of Ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest. 2005;34:171-198.
76. Morinaga H, Tazawa K, Tagoh H, Muraguchi A, Fujimaki M. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res. 1994;85:1298-1303.
77. Kurashige S, Akuzawa Y, Endo F. Effects of Lentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol Immunotoxicol. 1997;19:175-183.
78. Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). J Altern Complement Med. 2002;8:581-589.
79. Kasai H, He LM, Kawamura M, et al. IL-12 production induced by Agaricus blazei fraction H (ABH) involves toll-like receptor (TLR). Evid Based Complement Alternat Med. 2004;1:259-267.
80. Shao BM, Dai H, Xu W, Lin ZB, Gao XM. Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun. 2004;323:133-141.
81. Hsu HY, Hua KF, Lin CC, Lin CH, Hsu J, Wong CH. Extract of Reishi polysaccharides induces cytokine expression via TLR4-modulated protein kinase signaling pathways. J Immunol. 2004;173:5989-5999.
82. Gao Y, Tang W, Dai X, et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food. 2005;8:159-168.
83. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002;60:640-644.
84. Matsuzaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol. 2000;78:67-73.
85. Nagao F, Nakayama M, Muto T, Okumura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol Biochem. 2000;64:2706-2708.
86. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis. 2001;22:599-605.
87. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001;20:149-156.
88. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol. 2001;21:264-271.
89. Lim BK, Mahendran R, Lee YK, Bay BH. Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res. 2002;93:36-41.
90. Hori T, Kiyoshima J, Yasui H. Effect of an oral administration of Lactobacillus casei strain Shirota on the natural killer activity of blood mononuclear cells in aged mice. Biosci Biotechnol Biochem. 2003;67:420-422.
91. Parra MD, Martinez de Morentin BE, Cobo JM, Mateos A, Martinez JA. Daily ingestion of fermented milk containing Lactobacillus casei DN114001 improves innate-defense capacity in healthy middle-aged people. J Physiol Biochem. 2004;60:85-91.
92. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Antitumor activity and action mechanisms of Lactobacillus casei through the regulation of immune responses. Biofactors. 2004;22:63-66.
93. Morimoto K, Takeshita T, Nanno M, Tokudome S, Nakayama K. Modulation of natural killer cell activity by supplementation of fermented milk containing Lactobacillus casei in habitual smokers. Prev Med. 2005;40:589-594.
94. Fahr MJ, Kornbluth J, Blossom S, Schaeffer R, Klimberg VS. Harry M. Vars Research Award. Glutamine enhances immunoregulation of tumor growth. JPEN J Parenter Enteral Nutr. 1994;18:471-476.
95. Klimberg VS, Kornbluth J, Cao Y, Dang A, Blossom S, Schaeffer RF. Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res. 1996;63:293-297.
96. Shewchuk LD, Baracos VE, Field CJ. Dietary L-glutamine supplementation reduces the growth of the Morris hepatoma 7777 in exercise-trained and sedentary rats. J Nutr. 1997;127:158-166.
97. Kaufmann Y, Kornbluth J, Feng Z, Fahr M, Schaefer RF, Klimberg VS. Effect of glutamine on the initiation and promotion phases of DMBA-induced mammary tumor development. JPEN J Parenter Enteral Nutr. 2003;27:411-418.
98. Yakar I, Melamed R, Shakhar G, et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469-479.
99. Kundu N, Walser TC, Ma X, Fulton AM. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005;54:981-987.
100. Porzsolt F, Wolf W. Modulation of natural killer activity by aspirin: I. In vitro effect of aspirin. J Interferon Res. 1983;3:11-17.
101. Uhlenbruck G, Lotzerich H, Bernhardt J, Rogalla K. Acetylsalicylic acid has no effects on various isolated immune cells in vitro. Eur J Appl Physiol Occup Physiol. 1993;66:473-476.
102. Kang BY, Chung SW, Kim SH, Cho D, Kim TS. Involvement of nuclear factor-kappaB in the inhibition of interleukin-12 production from mouse macrophages by baicalein, a flavonoid in Scutellaria baicalensis. Planta Med 2003;69:687-691.
103. Kang BY, Kim SH, Cho D, Kim TS. Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappaB DNA binding activity by myricetin, a naturally occurring flavonoid. Arch Pharm Res. 2005;28:274-279.
104. Washizu J, Nishimura H, Nakamura N, Nimura Y, Yoshikai Y. The NF-kappaB binding site is essential for transcriptional activation of the IL-15 gene. Immunogenetics. 1998;48:1-7.
105. Hackstein H, Morelli AE, Larregina AT, et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol. 2001;166:7053-7062.
106. Hillen HF. Thrombosis in cancer patients. Ann Oncol. 2000;11 (suppl 3):273-276.
107. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30:31-44.
108. Oeth P, Parry GC, Mackman N. Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol. 1997;17:365-374.
109. Mushiake H, Tsunoda T, Nukatsuka M, Shimao K, Fukushima M, Tahara H. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother. 2005;54:120-128.
110. Petrie HT, Klassen LW, Klassen PS, O'Dell JR, Kay HD. Selenium and the immune response: 2. Enhancement of murine cytotoxic T-lymphocyte and natural killer cell cytotoxicityin vivo. J Leukoc Biol. 1989;45:215-220.
111. Roy M, Kiremidjian-Schumacher L, Wishe HI, Cohen MW, Stotzky G. Selenium and immune cell functions. II. Effect on lymphocyte-mediated cytotoxicity. Proc Soc Exp Biol Med. 1990;193:143-148.
112. Roy M, Kiremidjian-Schumacher L, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium restores age-related decline in immune cell function. Proc Soc Exp Biol Med. 1995;209:369-375.
113. Mizuno M, Morimoto M, Minato K, Tsuchida H. Polysaccharides from Agaricus blazei stimulate lymphocyte T-cell subsets in mice. Biosci Biotechnol Biochem. 1998;62:434-37.
114. Cao LZ, Lin ZB. Regulatory effect of Ganoderma lucidum polysaccharides on cytotoxic T-lymphocytes induced by dendritic cells in vitro. Acta Pharmacol Sin. 2003;24:321-326.
115. Matsuzaki T, Hashimoto S, Yokokura T. Effects on antitumor activity and cytokine production in the thoracic cavity by intrapleural administration of Lactobacillus casei in tumor-bearing mice. Med Microbiol Immunol (Berl). 1996;185:157-161.
116. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 1997;315:1219-1222.
117. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg. 2004;389:299-305.
118. Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer. 2003;89:1116-1122.
119. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer. 2004;91:1742-1750.
120. Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer. 2005;92:711-721.
121. Cai D, Frantz JD, Tawa NE, Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119:285-298.
122. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer. 1997;76:1035-1040.
123. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer. 2001;84:1599-1601.
124. Gomes-Marcondes MC, Smith HJ, Cooper JC, Tisdale MJ. Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer. 2002;86:1628-1633.
125. Tisdale MJ. Tumor-host interactions. J Cell Biochem. 2004;93:871-877.
126. Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J, Wainer IW. The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest. 2004;22:866-870.
127. Whitehouse AS, Khal J, Tisdale MJ. Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway. Br J Cancer. 2003;89:737-745.
128. Wyke SM, Khal J, Tisdale MJ. Signalling pathways in the induction of proteasome expression by proteolysis-inducing factor in murine myotubes. Cell Signal. 2005;17:67-75.
129. Smith HJ, Wyke SM, Tisdale MJ. Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2) C(12) myotubes. Br J Cancer. 2004;90:1850-1857.
130. Smith HJ, Wyke SM, Tisdale MJ. Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate. Cancer Res. 2004;64:8731-8735.
131. Panton LB, Rathmacher JA, Baier S, Nissen S. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Nutrition. 2000;16:734-739.
132. Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. J Nutr. 2001;131:2049-2052.
133. Alon T, Bagchi D, Preuss HG. Supplementing with beta-hydroxy-beta- methylbutyrate (HMB) to build and maintain muscle mass: a review. Res Commun Mol Pathol Pharmacol. 2002;111:139-151.
134. Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005;65:277-283.
135. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol. 1991;41:103-107.
136. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604-3609.
137. Jho DH, Babcock TA, Tevar R, Helton WS, Espat NJ. Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy. JPEN J Parenter Enteral Nutr. 2002;26:291-297.
138. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996;12:S27-S30.
139. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80-86.
140. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177-184.
141. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.
142. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
143. Tessitore L, Costelli P, Baccino FM. Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem J. 1994;299:71-78.
144. McCarty M. Pre-administration of high-dose aspirin or salicylate, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers - an example of pro-apoptotic signal modulation therapy. Med Hypotheses. In press.
145. Sadik CD, Sies H, Schewe T. Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action. Biochem Pharmacol 2003;65:773-781.
146. Shimoi K, Okada H, Furugori M, et al. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. 1998;438:220-224.
147. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem. 1999;63:896-899.
148. Bagli E, Stefaniotou M, Morbidelli L, et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 2004;64:7936-7946.
149. Kimball SR, Jefferson LS. Control of protein synthesis by amino acid availability. Curr Opin Clin Nutr Metab Care. 2002;5:63-67.
150. Hammarqvist F, Sandgren A, Andersson K, et al. Growth hormone together with glutamine-containing total parenteral nutrition maintains muscle glutamine levels and results in a less negative nitrogen balance after surgical trauma. Surgery. 2001;129:576-586.
151. Boza JJ, Turini M, Moennoz D, et al. Effect of glutamine supplementation of the diet on tissue protein synthesis rate of glucocorticoid-treated rats. Nutrition. 2001;17:35-40.
152. Yoshida S, Kaibara A, Ishibashi N, Shirouzu K. Glutamine supplementation in cancer patients. Nutrition. 2001;17:766-768.
153. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000;24:133-139.
154. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002;183:471-479.
155. Marcora S, Lemmey A, Maddison P. Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr. 2005;24:442-454.
156. Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care. 2002;5:271-279.
157. Singleton JR, Feldman EL. Insulin-like growth factor-I in muscle metabolism and myotherapies. Neurobiol Dis. 2001;8:541-554.
158. Franch HA, Price SR. Molecular signaling pathways regulating muscle proteolysis during atrophy. Curr Opin Clin Nutr Metab Care. 2005;8:271-275.
159. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127-137.
160. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol. 2004;51 (suppl 1):S17-S22.
161. Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 2003;17:73-89.
162. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets. 2005;9:753-768.
163. Oh JS, Kucab JE, Bushel PR, et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia. 2002;4:204-217.
164. Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T, Hashizume K. IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J. 1999;46(suppl):S59-S62.
165. Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 2002;82:1377-1389.
166. Stoeltzing O, Liu W. Reinmuth N, et al. Regulation of hypoxia-inducible factor-lalpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol. 2003;163:1001-1011.
167. Boyd DB. Insulin and cancer. Integr Cancer Ther. 2003;2:315-329.
168. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate. 2003;56:201-206.
169. Barnard RJ. Prevention of cancer through lifestyle changes. Evid Based Complement Alternat Med. 2004;1:233-239.
170. Allen NE, Appleby PN, Davey GK, Key TJ. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer. 2000;83:95-97.
171. Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev. 2002;11:1441-1448.
172. McCarty MF. Insulin and IGF-I as determinants of low "Western" cancer rates in the rural third world. Int J Epidemiol. 2004;33:908-910.
173. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
174. Spencer EA, Appleby PN, Davey GK, Key TJ. Diet and body mass index in 38000 EPIC-Oxford meat-eaters, fish-eaters, vegetarians and vegans. Int J Obes Relat Metab Disord. 2003;27:728-734.
175. Newby PK, Tucker KL, Wolk A. Risk of overweight and obesity among semivegetarian, lactovegetarian, and vegan women. Am J Clin Nutr. 2005;81:1267-1274.
176. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065-1069.
177. Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME, Arjmandi BH. Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. J Nutr. 2002;132:2605-2608.
178. Arjmandi BH, Lucas EA, Khalil DA, et al. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J. 2005;4:8.
179. Gann PH, Kazer R, Chatterton R, et al. Sequential, randomized trial of a low-fat, high-fiber diet and soy supplementation: effects on circulating IGF-I and its binding proteins in premenopausal women. Int J Cancer. 2005;116:297-303.
180. Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park). 2005;19:853-861.
181. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
182. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657-1667.
183. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol. 2002;20:1446-1448.
184. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program). 2004:439-456.
185. Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 2: management. Oncology (Williston Park). 2005;19:1077-1084.
186. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor Vila and tissue factor. Lancet. 1995;346:1004-1005.
187. Keller T, Salge U, Konig H, Dodt J, Heiden M, Seitz R. Tissue factor is the only activator of coagulation in cultured human lung cancer cells. Lung Cancer. 2001;31:171-179.
188. Kwaan HC, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost. 2003;29:283-290.
189. Dvorak HF, Van DeWater L, Bitzer AM, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 1983;43:4434-4442.
190. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065-2067.
191. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997;272:26159-26165.
192. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63:2997-3000.
193. Caunt M, Huang YQ, Brooks PC, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost. 2003;1:2097-2102.
194. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30:31-44.
195. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004;10:6-11.
196. Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P. Thrombin receptor expression is upregulated in prostate cancer. Prostate. 2006;66:273-282.
197. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-1948.
198. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 1995;15:612-621.
199. Oeth P, Parry GC, Mackman N. Regulation of the tissue factor gene in human monocytic cells: role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol. 1997;17:365-374.
200. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032-25039.
201. Yan SF, Lu J, Zou YS, et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem. 1999;274:15030-15040.
202. Yan SF, Lu J, Zou YS, et al. Protein kinase C-beta and oxygen deprivation: a novel Egr-1-dependent pathway for fibrin deposition in hypoxemic rasculature. J Biol Chem. 2000;275:11921-11928.
203. Semenza GL. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res. 2000;1:159-162.
204. Shell GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:301-307.
205. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65:7462-7469.
206. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-1302.
207. Thorngren M, Gustafson A, Wohlfart G. Effects of acetylsalicylic acid on platelet aggregation before and during increase in dietary eicosapentaenoic acid. Haemostasis. 1983;13:244-247.
208. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr. 1989;49:1211-1216.
209. Franconi F, Bennardini F, Mattana A, et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr. 1995;61:1115-1119.
210. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987;43:1110-1111.
211. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol 1990;84:139-143.
212. Suzuki Y, Kondo K, Matsumoto Y, et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci. 2003;73:1289-1298.
213. Cesarone MR, Belcaro G, Nicolaides AN, et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial. Angiology. 2003;54:531-539.
214. Urano T, Ihara H, Umemura K, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. 2001;276:24690-24696.
215. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002;106:2442-2447.
216. Kopp CW, Kopp HP, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11:950-956.
217. Song KS, Kim HK. Plasma levels of tissue factor antigen in patients with non-insulin-dependent diabetes mellitus. Yonsei Med J. 2004;45:38-42.
218. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002;132:241-252.
219. Nieuwdorp M, Stroes ES, Meijers JC, Buller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005;5:155-159.
220. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005;12:549-583.
221. Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord. 2000;1:253-263.
222. Yamamoto A, Miyazaki T, Kadono Y, et al. Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res. 2002;17:612-621.
223. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol. 2004;172:5940-5947.
224. Ogasawara T, Katagiri M, Yamamoto A, et al. Osteoclast differentiation by RANKL requires NF-kappaB-mediated down-regulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res. 2004;19:1128-1136.
225. Ruocco MG, Maeda S, Park JM, et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med. 2005;201:1677-1687.
226. Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem. 2001;276:46661-46670.
227. Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol. 2003;22:799-805.
228. Lindemann RK, Braig M, Hauser CA, Nordheim A, Dittmer J. Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. Biochem J. 2003;372:787-797.
229. Cho YM, Lewis DA, Koltz PF, et al. Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. J Endocrinol. 2004;181:179-190.
230. Richard V, Rosol TJ, Foley J. PTHrP gene expression in cancer: do all paths lead to Ets? Crit Rev Eukaryot Gene Expr. 2005;15:115-132.
231. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer. 1997;80:1572-1580.
232. Fox SW, Lovibond AC. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol. 2005;243:19-26.
233. Falzon M. The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression. Mol Cell Endocrinol. 1997;127:99-108.
234. Falzon M, Zong J. The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line. Endocrinology. 1998;139:1046-1053.
235. Tovar Sepulveda VA, Falzon M. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE. Mol Cell Endocrinol. 2003;204:51-64.
236. Tovar Sepulveda VA, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology. 2002;143:596-606.
237. Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept. 2002;105:109-120.
238. Shen X, Qian L, Falzon M. PTH-related protein enhances MCF-7 breast cancer cell adhesion, migration, and invasion via an intracrine pathway. Exp Cell Res. 2004;294:420-433.
239. Asadi F, Kukreja S. Parathyroid hormone-related protein in prostate cancer. Crit Rev Eukaryot Gene Expr. 2005;15:15-28.
240. Kusakabe A, Francis MJ. Quantitative ultrastructural analyses of rabbit osteoclasts: the effect of in vivo treatment with sodium salicylate. Nippon Seikeigeka Gakkai Zasshi. 1984;58:349-360.
241. Soekanto A, Ohya K, Ogura H. The effect of sodium salicylate on the osteoclast-like cell formation and bone resorption in a mouse bone marrow culture. Calcif Tissue Int. 1994;54:290-295.
242. Soekanto A. Inhibition of osteoclast-like cell formation by sodium salicylate and indomethacin in mouse bone marrow culture. Jpn J Pharmacol. 1994;65:27-34.
243. Galasko CS, Samuel AW, Rushton S, Lacey E. The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis. Br J Surg. 1980;67:493-496.
244. Johnson JR, Miller AJ. The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study. Palliat Med. 1994;8:129-135.
245. Pytlik M, Janiec W, Misiarz-Myrta M, Gubala I. Effects of simvastatin on the development of osteopenia caused by ovariectomy in rats. Pol J Pharmacol 2003;55:63-71.
246. Noa M, Mas R, Mendoza S, Gamez R, Mendoza N, Gonzalez J. Policosanol prevents bone loss in ovariectomized rats. Drugs Exp Clin Res. 2004;30:117-123.
247. Fernandes G, Lawrence R, Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. Prostaglandins Leukot Essent Fatty Acids. 2003;68:361-372.
248. Sun D, Klishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res. 2003;18:1206-1216.
249. Terano T. Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis. World Rev Nutr Diet. 2001;88:141-147.
250. Oxlund H, Andreassen TT. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone. 2004;34:609-618.
251. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218-2219.
252. Weiss LA, Barrett-Connor E, Von Muhlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am J Clin Nutr. 2005;81:934-938.
253. Schlienger RG, Meier CR. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs Aging. 2003;20:321-336.
254. Schoofs MW, Sturkenboom MC, van der KM, Hofman A, Pols HA, Stricker BH. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res. 2004;19:1525-1530.
255. Solomon DH, Finkelstein JS, Wang PS, Avorn J. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf. 2005;14:219-226.
256. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol. 1999;56:131-140.
257. Larsson CL, Johansson GK. Dietary intake and nutritional status of young vegans and omnivores in Sweden. Am J Clin Nutr. 2002;76:100-106.
258. Clark LC, Combs GFJ, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-1963.
259. Rayman MP, Rayman MP. The argument for increasing selenium intake. Proc Nutr Soc. 2002;61:203-215.
260. Mattson MP, Kruman II, Duan W. Folic acid and homocysteine in age-related disease. Ageing Res Rev. 2002;1:95-111.
261. Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr. 2003;22:1-8.
262. Knekt P, Ritz J, Pereira MA, et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 2004;80:1508-1520.
263. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89:552-572.
264. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80:1678S-1688S.
265. Devaraj S, Jialal I. Failure of vitamin E in clinical trials: is gamma-tocopherol the answer? Nutr Rev. 2005;63:290-293.
266. Weber P. Vitamin K and bone health. Nutrition. 2001;17:880-887.
267. Bugel S. Vitamin K and bone health. Proc Nutr Soc. 2003;62:839-843.
268. Shea B, Wells G, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002;23:552-559.
269. Yamori Y, Mizushima S. A review of the link between dietary magnesium and cardiovascular risk. J Cardiovasc Risk. 2000;7:31-35.
270. Maier JA. Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med. 2003;24:137-146.
271. Shechter M, Merz CN, Paul-Labrador M, et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999;84:152-156.
272. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care. 2004;27:2741-2751.
273. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75:216-230.
274. Granado F, Olmedilla B, Blanco I. Nutritional and clinical relevance of lutein in human health. Br J Nutr. 2003;90:487-502.
275. McCarty MF. Point of view - a role for "nutritional insurance" supplementation in preventive medicine. Med Hypotheses. 1981;7:171-185.
276. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res. 2000;6:1-10.
277. Brewer GJ. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets. 2005;5:195-202.
278. Boros LG, Brandes JL, Lee WN, et al. Thiamine supplementation to cancer patients: a double edged sword. Anticancer Res. 1998;18:595-602.
279. Comin-Anduix B, Boren J, Martinez S, et al. The effect of thiamine supplementation on tumour proliferation: a metabolic control analysis study. Eur J Biochem. 2001;268:4177-4182.
280. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004;80:1123-1128.
281. Young MV, Schwartz GG, Wang L, et al. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis. 2004;25:967-971.
282. Bises G, Kallay E, Weiland T, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem. 2004;52:985-989.
283. Townsend K, Banwell CM, Guy M, et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 2005;11:3579-3586.
284. Matilainen M, Malinen M, Saavalainen K, Carlberg C. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res. 2005;33:5521-5532.
285. Lowe L, Hansen CM, Senaratne S, Colston KW. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res. 2003;164:99-110.
286. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs - a brief overview. Mol Cell Biochem. 2003;253:247-254.
287. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res. 2003;164:205-221.
288. Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003;164:371-377.
289. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16:83-95.
290. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003;164:239-246.
291. Oades GM, Dredge K, Kirby RS, Colston KW. Vitamin D receptor-dependent antitumour effects of 1.25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002;90:607-616.
292. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol. 2003;84:181-192.
293. Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst. 2003;95:896-905.
294. Overbergh L, Decallonne B, Valckx D, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol. 2000;120:139-146.
295. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005;51:32-36.
296. Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control. 2004;15:149-158.
297. Moan J, Porojnicu AC, Robsahm TE, et al. Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B. 2005;78:189-193.
298. Porojnicu AC, Robsahm TE, Ree AH, Moan J. Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D. Br J Cancer. 2005;93:571-574.
299. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73:288-294.
300. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842-856.
301. Helming L, Bose J, Ehrchen J, et al. 1 α,25-dihydroxyvitamin D3 is a potent suppressor of interferon-γ mediated macrophage activation. Blood. 2005;106:4351-4358.
302. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136-1142.
303. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53:422-430.
304. McCarty MF. Chromium meta-analysis. Am J Clin Nutr. 2003;78:191-192.
305. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004;262:247-260.
306. Evans GW, Meyer LK. Life span is increased in rats supplemented with a chromium-pyridine-2-carboxylate complex. Adv Sci Res. 1994;1:19-23.
307. Holzenberger M. The role of insulin-like signalling in the regulation of ageing. Horm Res. 2004;62(suppl 1):89-92.
308. Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology. 2005;146:3718-3723.
309. Fung TT, Manson JE, Solomon CG, Liu S, Willet WC, Hu FB. The association between magnesium intake and fasting insulin concentration in healthy middle-aged women. J Am Coll Nutr. 2003;22:533-538.
310. McCarty MF. Magnesium may mediate the favorable impact of whole grains on insulin sensitivity by acting as a mild calcium antagonist. Med Hypotheses. 2005;64:619-627.
311. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care. 2005;28:1175-1181.
312. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003;26:1147-1152.
313. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G, et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance: a double-blind placebo-controlled randomized trial. Diabetes Metab. 2004;30:253-258.
314. Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA. 2005;293:86-89.
315. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546-553.
316. Jiang C, Jiang W, Ip C, Ganther H, Lu J. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog. 1999;26:213-225.
317. Jiang C, Ganther H, Lu J. Monomethyl selenium - specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog. 2000;29:236-250.
318. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of ariticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res. 2004;10:2561-2569.
319. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2004;2:632-642.
320. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005;65:3735-3744.
321. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000;20:1391-1414.
322. Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr. 2005;135:2030S-2031S.
323. Karas M, Amir H, Fishman D, et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer. 2000;36:101-111.
324. Liu C, Lian F, Smith DE, Russell RM, Wang XD. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res. 2003;63:3138-3144.
325. Li D, Sinclair A, Mann N, et al. The association of diet and thrombotic risk factors in healthy male vegetarians and meat-eaters. Eur J Clin Nutr. 1999;53:612-619.
326. Laidlaw SA, Shultz TD, Cecchino JT, Kopple JD. Plasma and urine taurine levels in vegans. Am J Clin Nutr. 1988;47:660-663.
327. McCarty MF. Sub-optimal taurine status may promote platelet hyperaggregability in vegetarians. Med Hypotheses. 2004;63:426-433.
328. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
329. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
330. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731-2735.
331. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938-6943.
332. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917-12922.
333. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
334. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
335. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
336. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939-952.
337. Erber R, Thurnher A, Katsen AD, et al. Combined Inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
338. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001;28:27-33.
339. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004;64:1475-1482.
340. Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ. Topotecan blocks hypoxia-inducible factor-lalpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005;65:4775-4781.
341. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biamarkers Prev. 2003;12:933-939.
342. Gallo D, Giacomelli S, Ferlini C, et al. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer. 2003;39:2403-2410.
343. Singh RP, Mallikarjuna GU, Sharma G, et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004;10:8641-8647.